H-SVGGVFTSV-OH

Ref. 3D-PP44140

Informations sur le produit

• Nom: H-SVGGVFTSV-OH
• Synonymes: NH2-Ser-Val-Gly-Gly-Val-Phe-Thr-Ser-Val-OH

Description

Peptide H-SVGGVFTSV-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-SVGGVFTSV-OH include the following: Single chain MHC trimer (SCT)-based DNA vaccines for pathogen protection S Kim - 2011 - search.proquest.comhttps://search.proquest.com/openview/71ba09a094222624d0392282292647d1/1?pq-origsite=gscholar&cbl=18750 Single chain MHC trimer-based DNA vaccines for pathogen protection S Kim - 2011 - openscholarship.wustl.eduhttps://openscholarship.wustl.edu/etd/598/ Detection and validation of HLA Class I presented viral epitopes using T cell receptor mimics (APP2P. 107) S Kaabinejadian, C McMurtrey, S Kim - The Journal of , 2014 - journals.aai.orghttps://journals.aai.org/jimmunol/article/192/1_Supplement/43.8/53947 A Hydrogen Peroxide-Inactivated Virus S Diamond, PP Patil, IJ Amanna, MK Slifka, MAK Pinto - J. Virol, 2013 - researchgate.nethttps://www.researchgate.net/profile/Amelia-Pinto-2/publication/233879667_A_Hydrogen_Peroxide-Inactivated_Virus_Vaccine_Elicits_Humoral_and_Cellular_Immunity_and_Protects_against_Lethal_West_Nile_Virus_Infection_in_Aged_Mice/links/02e7e53a8fc45aeb73000000/A-Hydrogen-Peroxide-Inactivated-Virus-Vaccine-Elicits-Humoral-and-Cellular-Immunity-and-Protects-against-Lethal-West-Nile-Virus-Infection-in-Aged-Mice.pdf Increased frequency of Tim-3 expressing T cells is associated with symptomatic West Nile virus infection MC Lanteri , MS Diamond , JP Law, GM Chew, S Wu - PloS one, 2014 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0092134 Advances in vaccinia virus-based vaccine vectors, with applications in flavivirus vaccine development L Xie, Y Li - Vaccine, 2022 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X22013111 Expanding the targets available to therapeutic antibodies via novel disease-specific markers JA Weidanz , WH Hildebrand - International reviews of immunology, 2011 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.3109/08830185.2011.608136 Development of Antigen-Specific Memory CD8+ T Cells Following Live-Attenuated Chimeric West Nile Virus Vaccination HL Smith , TP Monath, P Pazoles - Journal of Infectious , 2011 - academic.oup.comhttps://academic.oup.com/jid/article-abstract/203/4/513/2192151 Enhanced direct major histocompatibility complex class I self-antigen presentation induced by Chlamydia infection ED Cram, RS Simmons, AL Palmer - Infection and , 2016 - Am Soc Microbiolhttps://journals.asm.org/doi/abs/10.1128/iai.01254-15 Chlamydia spp. development is differentially altered by treatment with the LpxC inhibitor LPC-011 ED Cram, DD Rockey, BP Dolan - BMC microbiology, 2017 - Springerhttps://link.springer.com/article/10.1186/s12866-017-0992-8 Primary and Secondary Immune Responses During Sequential West Nile Virus and Japanese Encephalitis Virus Infections: A Dissertation DW Trobaugh - 2012 - repository.escholarship.umassmed https://repository.escholarship.umassmed.edu/handle/20.500.14038/31925 The unfolded protein response reveals eIF2alpha phosphorylation as a critical factor for direct MHC Class I antigen presentation BS Nagamine, J Godil, BP Dolan - ImmunoHorizons, 2021 - journals.aai.orghttps://journals.aai.org/immunohorizons/article/5/3/135/3799 Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens A Volz, S Lim, M Kaserer, A Lulf, L Marr, S Jany - Vaccine, 2016 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X16002139

• Marque: Biosynth